Brawn Biotech Limited (530207) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Brawn Biotech Limited ₹20.77, price ₹24.60, upside -15.6%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Brawn Biotech Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹13.80 – ₹41.70 · fair‑value band ₹15.63 – ₹52.88 · the ₹24.60 price screens above the ₹20.77 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Brawn Biotech in your weekly email
Every Wednesday you see whether Brawn Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Brawn Biotech Limited engages in the wholesale of pharmaceutical and medical goods in India and internationally. It offers various pharmaceutical formulations, including antibacterial, cardiovascular, antidiabetic, analgesic, gastrointestinal, antifungal, skin care, antipsychotic, antiasthmatic, antacid, antimalarial, and nutritional products.
Show more
Brawn Biotech Limited engages in the wholesale of pharmaceutical and medical goods in India and internationally. It offers various pharmaceutical formulations, including antibacterial, cardiovascular, antidiabetic, analgesic, gastrointestinal, antifungal, skin care, antipsychotic, antiasthmatic, antacid, antimalarial, and nutritional products. The company was formerly known as Brawn Pharmaceuticals Limited and changed its name to Brawn Biotech Limited in November 2010. Brawn Biotech Limited was founded in 1985 and is based in Gurugram, India.
Stock analysis
Brawn Biotech Limited (530207) currently trades at ₹24.60, while our model-based Fair Value estimate is ₹20.77, 15.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹53.30 per share, and 8 of the 15 models we run sit above the ₹24.60 price.
Bear case: the DCF Models group reads lowest at ₹4.69, and 7 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹15.63 (bear) to ₹52.88 (bull), the price of ₹24.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Health Care sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Brawn Biotech Limited reported revenue of ₹170M in FY2026 versus ₹79.5M in FY2022, a compound +20.9%/yr. Reported net income was ₹9.4M in FY2026.
Key figures
Market cap ₹73.8M (≈ $766K) · P/E ratio 6.2 · P/S ratio 0.34 · EPS (TTM) ₹−5.99 · Net margin 5.5% · Return on equity −4,267% · Return on assets (EBIT) −8.1% · Operating margin −2.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 38% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Health Care peers we cover trades at 10% fair-value upside, at −16%, 530207 screens richer than that median.
Fair Value models
Bear ₹15.63Fair Value ₹20.77Bull ₹52.88
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+26.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.5%
Start year 2021 (pandemic). Over 10 years: −9.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
’14
’15
’16
’17
’18
’19
’20
’21
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.7% (2021) → −2.6% (2026)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+43.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +37.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside−19.0% · Above median
Profitability
Return on assets0.0% · Above median
Net margin (TTM)−2.6% · Below median
Operating margin (TTM)−2.9% · Below median
Growth and dividend
Revenue growth−18.3% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Brawn Biotech Limited (530207) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹20.77 versus a price of ₹24.60, about −16% upside (overvalued).
What is the fair value of 530207?
Our model-based fair value for Brawn Biotech Limited is ₹20.77 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹24.60.
What is the quality score of 530207?
Brawn Biotech Limited has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Brawn Biotech Limited (530207)?
Our model-based price target is the fair value of ₹20.77 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario ₹15.63, optimistic scenario ₹52.88. It is a calculation from audited fundamentals, not an analyst target.
What is the Brawn Biotech Limited stock forecast for 2026?
Our models put fair value at ₹20.77, about −16% upside versus a price of ₹24.60 (overvalued). Cautious scenario ₹15.63, optimistic scenario ₹52.88. The calculation is refreshed regularly with new filings.
What is the revenue of Brawn Biotech Limited (530207)?
Brawn Biotech Limited reported trailing-twelve-month revenue of about ₹370M (latest available figure, as of Sep 24, 2026).
What growth is priced into Brawn Biotech Limited (530207)?
For today's price to be fair in a discounted-cash-flow model, Brawn Biotech Limited would have to grow free cash flow by +43.1 % per year for five years (discount rate 12.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -13.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 530207 use?
Our models discount Brawn Biotech Limited at 12.9 %: a base by market capitalisation (nano), damped by beta 1.19, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Brawn Biotech Limited that is +43.1 % per year a year over ten years, using the same discount rate (12.9 %) and the same formula as our fair value.
How much growth has Brawn Biotech Limited (530207) delivered so far?
Over the past 5 years revenue at Brawn Biotech Limited grew -13.5 % a year. The price currently implies +43.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Brawn Biotech Limited (530207) growing?
The median revenue growth in the sector is +8.1 % a year. That is the yardstick for the growth priced into Brawn Biotech Limited (+43.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Brawn Biotech Limited (530207)?
The free-cash-flow yield on the price is 1.16 %: that much free cash flow Brawn Biotech Limited produces per unit of market value. When it exceeds the discount rate of our models (12.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Brawn Biotech Limited (530207)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Brawn Biotech Limited it is ₹20.77 per share (as of Sep 24, 2026), against a price of ₹24.60. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Brawn Biotech Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 530207 trades above its calculated fair value: price ₹24.60, fair value ₹20.77, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 530207?
No. The price is what the market pays today (₹24.60); the fair value is what the company's own numbers justify (₹20.77). For Brawn Biotech Limited the two are ₹3.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is Brawn Biotech Limited worth?
The market values Brawn Biotech Limited at about ₹73.8M (market capitalisation, as of Sep 24, 2026). Per share that is ₹24.60; our models calculate a fair value of ₹20.77 per share.
What do the bullish and bearish scenarios say about 530207?
Our models span a range for Brawn Biotech Limited: cautious scenario ₹15.63, base ₹20.77, optimistic ₹52.88 per share (as of Sep 24, 2026, price ₹24.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 530207?
Brawn Biotech Limited trades at a price-to-earnings ratio of 6.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹20.77 is built from several models across several years.
How far is 530207 from its 52-week high?
Brawn Biotech Limited trades at ₹24.60, at its 52-week high of ₹24.60 and 38% above the low of ₹17.85 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹20.77 is for.
Which stocks are comparable to Brawn Biotech Limited?
From the same area (Health Care) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Brawn Biotech Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹24.60, calculated fair value ₹20.77 (−16%), Quality Score 54/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 530207 calculated?
We run Brawn Biotech Limited through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹20.77, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Brawn Biotech Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Brawn Biotech Limited (530207)?
The closing price on Oct 1, 2026 was ₹24.60. Our model-based fair value is ₹20.77, about −16% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Brawn Biotech Limited right now?
The model range is unusually wide (₹15.63 to ₹52.88). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Brawn Biotech Limited
How large is the market capitalisation of Brawn Biotech Limited (530207)?
The market capitalisation of Brawn Biotech Limited is ₹73.8M (≈ $766K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Brawn Biotech Limited (530207)?
The price-to-sales ratio of Brawn Biotech Limited is 0.34 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Brawn Biotech Limited (530207)?
Earnings per share at Brawn Biotech Limited are ₹−5.99 (price ÷ EPS = P/E 6.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Brawn Biotech Limited (530207)?
The net margin of Brawn Biotech Limited is 5.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Brawn Biotech Limited (530207)?
The return on equity (ROE) of Brawn Biotech Limited is −4,267% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Brawn Biotech Limited (530207)?
On an EBIT basis the return on assets of Brawn Biotech Limited is −8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Brawn Biotech Limited (530207)?
The operating margin of Brawn Biotech Limited is −2.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Brawn Biotech Limited (530207)?
Revenue at Brawn Biotech Limited is growing −18.3% versus a year earlier (3y avg −8.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Brawn Biotech Limited (530207)?
Earnings per share at Brawn Biotech Limited are growing −74.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Brawn Biotech Limited in the live analysis
One click puts Brawn Biotech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
